0
Protagonist Therapeutics, Inc. Banner Image

Protagonist Therapeutics, Inc. has reached its limit for free report views

Work for Protagonist Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Protagonist Therapeutics, Inc.

  • Ticker PTGX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Protagonist Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Newark, California
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development forMore the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.
Protagonist Therapeutics, Inc.

Most Recent Annual Report

Protagonist Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Protagonist Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports